Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR1D | P28221 | 2/20 | 0.54 |
| ▸ | HTR1B | P28222 | 2/20 | 0.54 |
| ▸ | HTR1F | P30939 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601701 | 0.90 | HTR6 (0.68) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3592630 | 0.88 | HTR6 (0.64) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3595920 | 0.88 | HTR6 (0.63) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3587283 | 0.88 | HTR6 (0.72) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3595374 | 0.87 | HTR6 (0.69) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5230698 | 0.86 | HTR6 (0.78) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5230637 | 0.85 | HTR6 (0.71) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5228940 | 0.84 | HTR6 (0.53) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL948738 | 0.79 | HTR6 (0.62) | HTR6 | |
| SCHEMBL6235303 | 0.78 | HTR6 (0.56) | HTR6KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649097-B2 | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| EP-1523486-B1 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-11-07 | — | — | EP | disclosed |
| US-20050203154-A1 | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
| EP-1523486-A2 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004000849-A2 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203154-A1 | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | HTR6 7/4885HTR1A 2/4885DRD2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.